04:02:55 EDT Sun 19 Sep 2021
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Hemostemix Inc
Symbol HEM
Shares Issued 756,811,552
Close 2020-09-22 C$ 0.01
Recent Sedar Documents

Hemostemix appoints interim chief medical officer

2020-09-23 08:51 ET - News Release

Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES DR. PIERRE LEIMGRUBER AS INTERIM CHIEF MEDICAL OFFICER

Hemostemix Inc. has appointed Dr. Pierre Leimgruber, MD, FACC, as its interim chief medical officer. A specialist in the prevention and treatment of cardiovascular disease, Dr. Leimgruber is board-certified in internal medicine, cardiovascular diseases, interventional cardiology and he has worked for 32 years as an interventional cardiologist, affiliated with four leading Spokane hospitals. Dr. Leimgruber also serves as clinical associate professor of medicine at the University of Washington School of Medicine in Seattle. Dr. Leimgruber received his medical degree from University of Zurich Medical School and trained with Andreas Gruentzig, MD, the inventor of balloon angioplasty, at Emory University Hospital in Atlanta. Dr. Leimgruber is the author of 26 peer-reviewed research studies published in leading medical journals.

"After performing thousands of angioplasties and stent placements in patients with severe coronary, carotid artery and in patients with peripheral artery disease (PAD) and severe critical limb ischemia (CLI), I keenly understand this market and the significant promise ACP-01 offers the millions of afflicted," said Dr. Leimgruber. "We know ACP-01's clinical outcomes and phase II open label data is world class to date," he said. "We know its medical applications -- CLI and PAD, angina, ischemic and dilated cardiomyopathy -- are unmet needs at a global scale," he continued. "Now we will see if the blind placebo-controlled phase II results enable the company to commercialize," said Dr. Leimgruber.

"I have known Dr. Leimgruber since 2008, when he was introduced to me by my good friend and co-founder, the late Roger Bergersen. As many shareholders know, Roger was ACP-01 recipient-patient No. 35, and a heart patient of Dr. Leimgruber's shortly after his procedure. So, Dr. Leimgruber knows how ACP-01 helped Roger beat the odds to live another 14.5 years. From his 32 years of interventional cardiology and first-hand knowledge of the outcomes of ACP-01 treatments, I am very thankful Dr. Leimgruber has agreed to help navigate the buildout of the company," said Thomas Smeenk, chief executive officer.

About Hemostemix Inc.

Hemostemix is a publicly traded autologous stem cell therapy company. A winner of the World Economic Forum technology pioneer award, Hemostemix developed and is commercializing its lead product ACP-01 for the treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia. ACP-01 has been used to treat over 300 patients, and it is the subject of a randomized, placebo-controlled, double-blind trial of its safety and efficacy in patients with advanced critical limb ischemia who have exhausted all other options to save their limb from amputation.

On Oct. 21, 2019, Hemostemix announced the results from its phase II CLI trial abstract entitled "Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Followup" which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to 4.5 years.

Hemostemix owns 91 patents across five patent families titled: regulating stem cells, in vitro techniques for use with stem cells, production from blood of cells of neural lineage and automated cell therapy.

We seek Safe Harbor.

© 2021 Canjex Publishing Ltd. All rights reserved.